Cadre Holdings Q2 2026 Call Affirms Solid Defense Demand, But Premium Valuation Persists

What happened

Cadre Holdings’ Q2 2026 earnings call highlighted continued strength in its survivability and nuclear safety segments, benefiting from multi-year defense programs and the Zircaloy acquisition. Backlog remained robust at $186.3 million, reflecting sustained demand for body armor, EOD equipment, and nuclear products. Management likely addressed supply chain and inflation risks, which persist as headwinds to margin expansion. The stock’s elevated multiples—44x P/E, 17.5x EV/EBITDA—limit near-term upside despite improving fundamentals. The call reinforced the view that Cadre is executing well but is already priced for perfection, warranting a defensive posture.

Implication

Investors should monitor program milestones (LSAPI, Next Gen Bomb Suit) and margin trends for signs of re-rating potential. Any slowdown in defense procurement or margin pressure would pressure the stock, while a successful ramp of new products and easing costs could justify the premium. For now, the risk-reward is balanced, favoring existing holders and patient buyers on dips.

Thesis delta

The Q2 2026 call did not materially alter the investment thesis. Cadre’s operational performance remains solid, supported by a $186.3 million backlog and multi-year tailwinds, but the stock’s premium valuation continues to constrain upside, keeping the rating at HOLD.